Fulvestrant
| Code | Size | Price |
|---|
| CDX-F0328-M025 | 25 mg | £96.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
Short Term: +4°C Long Term: -20°C
Documents
Further Information
Alternate Names/Synonyms:
ICI 182780; Faslodex; 7alpha-[9-[(RS)-(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17beta-diol
Appearance:
White or off white crystalline powder.
CAS:
129453-61-8
EClass:
32160000
Form (Short):
solid
Handling Advice:
Protect from light and moisture.
InChi:
InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1
InChiKey:
VWUXBMIQPBEWFH-WCCTWKNTSA-N
Long Description:
Chemical. CAS: 129453-61-8. Formula: C32H47F5O3S. MW: 606.77. Synthetic. Fulvestrant is a selective estrogen receptor degrader (SERD) that downregulates and degrades estrogen receptor alpha (ERalpha). It reduces dimerization and nuclear localization of the estrogen receptor (ER). Fulvestrant lowers the level of ER protein in human breast cancer cells. Fulvestrant inhibits the growth of ER-positive MCF-7 human breast cancer cells but not ER-negative BT-20 cells when used at a concentration of 1µg/ml. It also prevents tumor growth in MCF-7 and Br10 breast cancer mouse xenograft models when used at a single dose of 5 mg per animal. Fulvestrant is neuroprotective in vitro against neurotoxicity induced by glutamate- and amyloid-beta (1-42) (Abeta42) in primary rat hippocampal cells. Formulations containing fulvestrant have been used in the treatment of estrogen-sensitive breast cancer.
MDL:
MFCD00903953
Molecular Formula:
C32H47F5O3S
Molecular Weight:
606.77
Package Type:
Vial
Product Description:
Fulvestrant is a selective estrogen receptor degrader (SERD) that downregulates and degrades estrogen receptor alpha (ERalpha). It reduces dimerization and nuclear localization of the estrogen receptor (ER). Fulvestrant lowers the level of ER protein in human breast cancer cells. Fulvestrant inhibits the growth of ER-positive MCF-7 human breast cancer cells but not ER-negative BT-20 cells when used at a concentration of 1µg/ml. It also prevents tumor growth in MCF-7 and Br10 breast cancer mouse xenograft models when used at a single dose of 5 mg per animal. Fulvestrant is neuroprotective in vitro against neurotoxicity induced by glutamate- and amyloid-beta (1-42) (Abeta42) in primary rat hippocampal cells. Formulations containing fulvestrant have been used in the treatment of estrogen-sensitive breast cancer.
Purity:
>98% (HPLC)
SMILES:
OC1=CC=C2C(C[C@@H](CCCCCCCCCS(CCCC(F)(F)C(F)(F)F)=O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@H]4O)=C1
Solubility Chemicals:
Soluble in DMSO (20mg/ml), DMF (20mg/ml) or ethanol (20mg/ml).
Source / Host:
Synthetic
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
(1) A.E Wakeling, et al.; Cancer Res. 51, 3867 (1991) | (2) J.F. Robertson; Br. J. Cancer 85, 11 (2001) (Review) | (3) N. Bundred & A. Howell; Expert Rev. Anticancer Ther. 2, 151 (2002) (Review) | (4) C.K. Osborne, et al.; Br. J. Cancer 90, S2 (2004) (Review) | (5) S. Kansra, et al.; Mol. Cell Endocrinol. 239, 27 (2005) | (6) M. Dowsett, et al.; Breast Cancer Res. Treat. 93, S11 (2005) (Review) | (7) L. Zhao, et al.; J. Pharmacol. Exp. Ther. 319, 1124 (2006) | (8) P. Kabos & V.F. Borges; Expert Opin. Pharmacother. 11, 807 (2010) (Review) | (9) S.E. Wardell, et al.; Biochem. Pharmacol. 82, 122 (2011)